Literature DB >> 31565973

Toxicity profiling and prioritization of plant-derived antimalarial agents.

J Devillers1, H Devillers2.   

Abstract

Human malaria is the most widespread mosquito-borne life-threatening disease worldwide. In the absence of effective vaccines, prevention and treatment of malaria only depend on prophylaxis and drug-based therapy either in monotherapy or in combination. Unfortunately, the number of available antimalarial drugs presenting different mechanisms of action is rather limited. In addition, the appearance of drug-resistance in the parasite strains impacts the efficacy of the treatments. As a result, there is a crucial need to find new drugs to circumvent resistance problems. In the quest to identify new antimalarial agents a huge number of plant-derived compounds (PDCs) have been investigated. Surprisingly in the in silico PDC screening programs, toxicity filters are either never used or so simple that their interest is limited. In this context, the goal of this study was to show how to take advantage of validated toxicity QSAR models for refining the selection of PDCs. From an original data set of 507 PDCs collected from the literature, the use of toxicity filters for endocrine disruption, developmental toxicity, and hepatotoxicity in conjunction with classical pharmacokinetic filters allowed us to obtain a list of 31 compounds of potential interest. The pros and cons of such a strategy have been discussed.

Entities:  

Keywords:  Malaria; QSAR; pharmacokinetics; plant-derived compound; toxicity

Year:  2019        PMID: 31565973     DOI: 10.1080/1062936X.2019.1665844

Source DB:  PubMed          Journal:  SAR QSAR Environ Res        ISSN: 1026-776X            Impact factor:   3.000


  1 in total

1.  Treatment of Experimental Cerebral Malaria by Slow Release of Artemisone From Injectable Pasty Formulation.

Authors:  Jacob Golenser; Nadeen Salaymeh; Abd Alroof Higazi; Mohammed Alyan; Mahran Daif; Ron Dzikowski; Abraham J Domb
Journal:  Front Pharmacol       Date:  2020-06-12       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.